期刊文献+

重症肌无力胸腺瘤天然调节T细胞及其影响因素 被引量:4

Natural T regulatory cells and its influencing factors in thymomas complicated with myasthenia gravis
下载PDF
导出
摘要 目的研究伴重症肌无力(MG)胸腺瘤患者胸腺瘤中天然调节性T细胞(nTreg)的变化及其影响因素。方法采用免疫组化方法检测不同病理类型胸腺瘤中nTreg细胞的数量,通过实时定量反转录PCR检测不同病理类型胸腺瘤中FoxP3 mRNA及胸腺间质淋巴细胞生成素(thymic stromal lymphopoietin,TSLP)mRNA水平,并分析二者之间的关系。结果伴MG胸腺瘤中FoxP3+Treg细胞数量较正常胸腺组织减少,差异有统计学意义(P<0.01);伴MG胸腺瘤FoxP3 mRNA、TSLP mRNA转录水平较正常胸腺组织明显降低,差异有统计学意义(P<0.01);在各胸腺瘤亚型中,B1型FoxP3+Treg细胞数量,FoxP3 mRNA、TSLP mRNA转录水平最高;FoxP3 mRNA、TSLP mRNA水平呈显著正相关。结论伴MG胸腺瘤中nTreg减少,与胸腺瘤中TSLP转录水平下降有关,可能导致免疫调节功能紊乱,从而引起MG发病。 Objective To investigate the regulatory T cells (Treg) and its influencing factors in the thymomas complicated with myasthenia gravis (MG).Methods The numbers of FoxP3+ Treg cells were detected by immunohistochemical analysis,and the transcriptional levels of FoxP3 mRNA and thymic stromal lymphopoietin (TSLP) mRNA were quantitatively analyzed by real-time reverse transcription polymerase chain reaction (real-time RT-PCR).Results CD4+FoxP3+ nTreg ceils in thymomas were significantly decreased compared with normal thymus (P < 0.01) and the standard values of FoxP3 mRNA and TSLP mRNA were significantly decreased in thymomas (P < 0.01).Among the types of thymomas,the numbers of FoxP3+ Treg cells,standard values of FoxP3 mRNA and TSLP mRNA were higher in B1 organoid thymomas than other types of thymomas.There was a strong positive correlation between the FoxP3 mRNA transcriptional levels and the TSLP mRNA transcriptional levels.Conclusion These results suggest that there is decreased number of CD4+FoxP3+ Treg cells in thymomas in patients with MG and the decreased transcriptional levels of FoxP3 may be regulated by the decreased transcription of TSLP.The decrease of CD4+FoxP3+ Treg cells may interfere with the immune tolerance of patients with thymomas.
机构地区 解放军第
出处 《北京医学》 CAS 2013年第11期899-903,共5页 Beijing Medical Journal
关键词 重症肌无力 胸腺瘤 调节T细胞 双叉头转录因子 胸腺间质淋巴细胞生成素 Myasthenia gravis (MG) Thymomas Regulatory T cells FoxP3 Thymic stromal lymphopoietin
  • 相关文献

参考文献15

  • 1Hori S, Nomum T, Sakaguchi S. Control of regulatory T cell de- velopment by the transcription factor FoxP3. Science,2003,299: 1057-1061.
  • 2Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity,2000,12:431- 440.
  • 3Watanabe N, Hanabuchi S, Soumelis V, et al. Human thymic stro- mal lymphopoietin promotes dendritic cell-mediated CD4+ T cellhomeostatic expansion. Nat Immunol,2004,5:426-434.
  • 4Green EA, Gorelik L, McGregor CM, et al. CD4~CD25~ T regula- tory cells control anti-islet CD8~ T cells through TGF-I3 receptor interactions in type 1 diabetes. Proe Natl Aead Sei,2003,100: 10878-10883.
  • 5Arieha R, Feferman T, Berrih-Aknin S, et al. Experimen- tal myasthenia gravis in Aire-deficient mice: a link between Aire and regulatory T cells. Ann NY Aead Sci,2012,1275:107-113.
  • 6Thiruppathi M, Rowin J, Ganesh B, et al. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol,2012,145:209-223.
  • 7Masuda M, Matsumoto M, Tanaka S, et al. Clinical implication of peripheral CD4 +CD25 ~ regulatory T cells and Thl7 cells in myasthenia gravis patients. J Neuroimmunol,2010,225:123-131.
  • 8Wang Z, Wang W, Chen Y, et al. T helper type 17 cells expand in patients with myasthenia-associated thymoma. Stand J Im- munol,2012,76:54-61.
  • 9Balandina A, Lecart S, Dartevelle P, et al. Functional defect of regulatory CD4~CD25 q" ceils in the thymus of patients with au-toimmune myasthenia gravis. Blood,2005,105:735-741.
  • 10A1-Shami A, Spolski R, Kelly J, et al. A role for thymic stro- mal lymphopoietin in CD4 ~ T cell development. J Exp Med,2004,200:159-168.

二级参考文献11

  • 1Masaoka A,Monden Y,Nakahara K,et al. Follow-up study of thymomas with special reference to their clinical stages [Jl.Cancer, 1981,48(11 ) : 2485-2492.
  • 2Alfred J, Richard J J, Raina ME, et al. Myasthenia gravis : recommendations for clinical research standards [J]. Neurology,2000,55(1 ) : 16-23.
  • 3Drachman DP. Myasthenia gravis[J]. New Engl d Med, 1994,330(25) : 1797-1810.
  • 4Lewis JE,Wick MR,Scheithauer BW,et al. Thymoma. A clinical-pathologic review[J]. Cancer, 1987,60(11) : 2727-2743.
  • 5Regnard JF, Magdeleinat P, Dromer C,et al. Prognostic factors and long-term results after thymoma resection:a series of 307 patients[J]. J Thorac Cardiovasc Surg , 1996,112(2) :376-384.
  • 6Savvas N,Nestor LM, David KB,et al. Thymus in myasthenia gravis:comparison of CT and pathologic findings and clinical outcome after thymectomy[J]. Radiology, 1996,201 (2) : 471-474.
  • 7Aarli JA. Myasthenia gravis :antibodies to a cell-surface skeletal muscle antigen and their relation to neoplastic thymic epitheloid cells[J]. Neurology, 1984,34(Suppl 1 ) : 142.
  • 8Yamamoto AM,Gajdos P,Eymard B,et al. Anti-titin antibodies in myasthenia gravis:tight association with thymoma and heterogeneity of nonthymoma patients[J]. Arch Neurol, 2001,58(6) : 885-890.
  • 9Evoli A, Minise C,Di Sehino C,et al. Thymoma in patients with MG characteristics and long-term outcome[J]. Neurology, 2002,59 (12) : 1844-1850.
  • 10马维娅,涂来慧.用间接血凝技术检测重症肌无力患者血清中与胸腺瘤相关...[J].中华神经精神科杂志,1990,23(3):143-145. 被引量:2

共引文献8

同被引文献47

  • 1孙强,欧阳静萍,王云甫,何国厚.胸腺基质淋巴细胞生成素在重症肌无力患者胸腺组织中的表达[J].郧阳医学院学报,2010,29(4):333-334. 被引量:3
  • 2王秀云,许贤豪,孙宏,韩雄,张华,国红.重症肌无力病人的临床绝对评分法和相对评分法[J].中华神经科杂志,1997,30(2):87-90. 被引量:241
  • 3Zhang M,Zhou J, Zhao T,et al. Dissection of a circulating and Intrahepatlc CD4 (+)Foxp5 (+) T-ceil subpopulation in chronic hepatitis B virus (HBV) infection: a highly in- formative strategy for distinguishing chronic HBV infection states [J]. J Infect Dis, 2012,205 (7) : 1111-1120.
  • 4Banham AH. Cell-surface IL-7 receptor expression facili- tates the purification of FOXP3 (+) regulatory T cells [J]. Trends Immunol, 2006,27 (12) : 541-544.
  • 5Yu N, Li X,Song W,et al. CD4(+)CD25 (+)CD127 (low/ -) T cells: a more specific Treg population in human pe- ripheral blood [J]. Inflammation, 2012,35 (6) : 1773-1780.
  • 6Tsakiri N, Papadopoulos D, Denis MC, et al. TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-eell function and disease suppression in. EAE [J]. Eur J Immunol,2012,42(2) :403-412.
  • 7袁剑云,英立平.临床路径实施手册[M].北京:北京医科大学出版社,2012:84-86.
  • 8Li XL, Liu Y, Cao LL, et al. Atorvastatin-modified den- dritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines [J]. Mol Cell Neurosci ,2013,56 (2) :85-86.
  • 9Thornton AM, Korty PE, Tran DQ,et al. Expression of Helios,an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3 + T regulatory cells [J]. J hnmunol, 2010,184 ( 11 ) : 3433-3441.
  • 10Kim YC, Bhairavabhotla R,Yoon J,et al. Oligodeoxynu- cleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion [J]. Blood,2012,119 (4) :2810-2818.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部